Charles R. Scheper Recognized as a Great Living Cincinnatian
Bexion Pharmaceuticals, Inc. is proud to announce that its Chairman of the Board, Charles R. Scheper, has received the prestigious title of Great Living Cincinnatian. This honor, awarded by The Cincinnati Regional Chamber, celebrates outstanding community leaders whose achievements have positively influenced the Cincinnati region.
Significance of the Great Living Cincinnatian Award
The Great Living Cincinnatian recognition is one of the highest awards presented in the Cincinnati community. Individuals who receive this accolade are acknowledged for their exceptional service to the community and significant accomplishments in various fields—including business, civic engagement, and leadership. The award also honors those individuals who are committed to meeting the needs of others and who have brought favorable attention to their communities.
Background on Charles R. Scheper
Chuck Scheper has been at the helm of Bexion Pharmaceuticals since 2010, steering the company towards innovative advancements in oncology. Before joining Bexion, he held significant leadership roles, including Chief Operating Officer at Great American Financial Resources, a company worth approximately $20 billion. His extensive experience in the insurance and financial sectors has equipped him with the skills to navigate the complexities of the biopharmaceutical industry.
Moreover, Scheper’s personal journey as a cancer survivor has profoundly shaped his commitment to cancer-related causes. He has been involved with organizations such as the Cancer Support Community, serving as the National Board Chairperson. His advocacy work reflects his dedication to improving the lives of other cancer patients.
Community Impact
Speaking on Scheper's recent honor, Jim Beach, the CEO of Bexion Pharmaceuticals, expressed immense pride, stating, "Chuck embodies the values we strive for at Bexion and inspires us to continue making a difference in people's lives." This sentiment resonates with many in the community who have experienced his impactful leadership firsthand.
BXQ-350: Bexion's Lead Drug Candidate
Bexion's pioneering drug candidate, BXQ-350, represents a significant step forward in the treatment of solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN). BXQ-350 is a first-in-class biologic that has successfully completed several Phase 1 clinical trials, demonstrating robust safety and encouraging activity across various solid tumors.
The ongoing research and commitment to advancing BXQ-350 highlights Bexion’s dedication to addressing unmet medical needs and providing new options to patients suffering from difficult-to-treat conditions.
About Bexion Pharmaceuticals
Based on its groundbreaking research, Bexion Pharmaceuticals is focused on developing a new generation of biologic therapies that promise to change how solid tumor cancers and neuropathic pain are treated. With previous successes in oncology clinical trials for conditions including colorectal cancer and pediatric brain tumors, Bexion is navigating the exciting yet challenging path of drug development with a vision to broaden its portfolio into additional therapeutic areas.
About the Cincinnati Regional Chamber
The Cincinnati Regional Chamber serves as a vital organization for business and civic engagement, aiming to enhance economic prosperity and cultural vibrancy in the region. Through its leadership programs, advocacy efforts, and community events, the Chamber works diligently to create a thriving environment for businesses and residents alike.
Frequently Asked Questions
What is the Great Living Cincinnatian Award?
The Great Living Cincinnatian Award recognizes exceptional individuals for their contributions to the community, highlighting their leadership, service, and achievements.
Who is Charles R. Scheper?
Charles R. Scheper is the Chairman of Bexion Pharmaceuticals, a company focused on developing therapies for solid tumors and CIPN. He is also a cancer survivor and active community leader.
What is BXQ-350?
BXQ-350 is Bexion’s lead biologic drug candidate, currently in clinical trials for treating solid tumor cancers and CIPN, showing a promising safety profile and efficacy in initial studies.
How has Charles R. Scheper impacted the community?
Scheper has made significant contributions to cancer advocacy and community service, inspiring many through his leadership at Bexion Pharmaceuticals and local organizations.
How can I learn more about Bexion Pharmaceuticals?
To learn more about Bexion Pharmaceuticals and its innovative drug candidates, you can visit the company’s official website or follow their latest news outlets.
